Select Publications
De Vos S et al. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results. Proc ASH 2006;Abstract 694.
Hallek M et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Proc ASH 2008;Abstract 325.
Kahl B et al. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Proc ASH 2007;Abstract 1351.
Knauf WU et al. Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: An updated analysis from an international phase III study. Proc ASH 2008;Abstract 2091.
Osterborg A et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial. Proc ASH 2008;Abstract 328.
Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: Results of a randomized phase III study of the study group indolent lymphomas (StiL). Proc ASH 2008;Abstract 2596.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Gail J Roboz, MD
- Select publications
Stephanie A Gregory, MD
- Select publications
Sundar Jagannath, MD
- Select publications
Guillermo Garcia-Manero, MD
- Select publications
